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Abstract The effect of plant flavonoids on intercellular
adhesion molecule-1 (ICAM-1) expression in human keratino-
cyte was investigated. ICAM-1 is known to mediate skin
inflammation. Among the flavonoids tested, taxifolin was the
most potent in inhibiting interferon Q (IFNQ)-induced ICAM-1
protein as well as mRNA expression in human keratinocytes.
Much smaller dosages of taxifolin were required in primary
keratinocytes compared to HaCaT (immortalized cell) to achieve
similar levels of inhibition in the inducible ICAM-1 expression.
Regulation of inducible ICAM-1 expression by taxifolin was at
transcriptional level by inhibiting the activation of signal
transducers and activators of transcription (STAT)1 and protein
tyrosine phosphorylation of Janus kinase (JAK)1 suggesting that
the JAK^STAT pathway may be the molecular site of action of
taxifolin. Finally, taxifolin pre-treatment also potently inhibited
IFNQ-induced ICAM-1 expression in a reconstructed human skin
equivalent suggesting therapeutic potential of taxifolin in skin
pathological conditions related to increased cell adhesion and
inflammation. - 2002 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
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1. Introduction
Skin in£ammatory diseases are very common and often
treated inadequately in spite of long continuous e¡orts.
Only a limited number of agents such as corticosteroid,
anti-histamine or immunosuppressant are available that are
known to be e¡ective in the treatment of skin in£ammation.
However, all of these agents have limitations, for example,
anti-histamines are not as potent as other agents and may
be used merely as supplemental therapy [1,2]. Corticosteroid
and immunosuppressant on the other hand have potent inhib-
itory e¡ects, however, only very few of these agents are suit-
able for long-term continuous medication [3,4]. Thus, long-
term and safe control of skin in£ammation is still a big chal-
lenge.
The in£ammatory or immune response requires the cell^cell
interaction between leukocytes and targets cells. The forma-
tion of constitutive and inducible adhesion molecule com-
plexes is necessary for the interaction of these cells [5]. Di¡er-
ential expression of intercellular adhesion molecule-1 (ICAM-
1), a member of the immunoglobulin gene superfamily, in the
epidermis plays a critical role in the regulation of cutaneous
in£ammation, immunologic reactions and tissue repair.
ICAM-1 mediates the ¢rm binding of a variety of leukocytes
to the target cells via its interaction with lymphocyte function-
associated antigen 1 (LAF-1) or Mac-1 (CD11b/CD18) ex-
pressed on the circulating white blood cells [6,7].
Plant £avonoids are reported to have therapeutic potentials
because of their anti-oxidant, anti-in£ammatory, anti-cancer,
anti-allergic or anti-ischemic properties [8^15]. Most of the
biological activity of £avonoids is attributed to their redox
modulatory and protein kinase inhibitory properties. We
have recently shown that the £avonoid quercetin potently in-
hibits inducible ICAM-1 expression in endothelial cells by
inhibiting the Jun-N-terminal kinase pathway [16]. Further-
more, pine bark extract, a complex £avonoid, also inhibited
ICAM-1 expression in HaCaT cells by inhibiting signal trans-
ducers and activators of transcription (STAT) 1 activation
[17]. In vivo, skin penetration studies of £avonoids provide
evidence that the £avonoids after topical application can be
absorbed from the skin surface and penetrate into deeper skin
layers [18]. Katiyar et al. observed that topical application of
(3)-epigallocatechin-3-gallate (3 mg/2.5 cm2), the major poly-
phenolic constituent in green tea, before UVB (4 MED) ex-
posure to human skin signi¢cantly blocked UVB-induced in-
¢ltration of leukocytes [19]. The present study was aimed to
investigate the e¡ect of representative compounds of various
£avonoid classes on inducible ICAM-1 expression. Further-
more, the molecular site of regulation of ICAM-1 by £avo-
noids was also investigated.
2. Materials and methods
2.1. Cells and cell culture
The immortalized human keratinocyte line HaCaT was grown in
Dulbecco’s modi¢ed Eagle’s medium (Life Technologies, Gaithers-
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burg, MD, USA) supplemented with 10% fetal bovine serum (FBS),
100 U/ml penicillin and 100 Wg/ml streptomycin. Primary human epi-
dermal keratinocytes (HEK) were obtained from a 25-year-old male
(Cascade Biologics, Portland, OR, USA). HEK were grown in Me-
dium 154 supplemented with human keratinocyte growth supplement
and PSA (penicillin, streptomycin and amphotericin B) solution (Cas-
cade Biologics). Human Jurkat T-cells clone E6-1 (American Type
Culture Collection, Bethesda, MD, USA) were grown in RPMI
1640 medium supplemented with 10% FBS, 100 U/ml penicillin and
100 Wg/ml streptomycin, 110 mg/l sodium pyruvate and 2 mM L-glu-
tamine. Cells were pre-treated with various classes of £avonoids (Fig.
1) and then activated with interferon Q (IFNQ). Taxifolin and other
£avonoid stock solutions for cell treatment were prepared fresh in
dimethyl sulfoxide (DMSO) at concentrations such that the ¢nal con-
centration of the solvent in cell suspension never exceeded 0.1%. A
three-dimensional (3D) model of HEK (EpiDerm; Kurabo, Osaka,
Japan) was used for immunohistochemical experiments. This model
consists of normal human-derived epidermal keratinocytes, grown on
permeable cell culture inserts that have the potential to form multi-
layered and highly di¡erentiated keratinocytes [20]. The EpiDerm
assay kit contains 24 units of 8-mm diameter tissue samples. The
epidermal equivalents were removed from the 24-well plates contain-
ing agarose and equilibrated to 37‡C, 5% CO2 for 1 h with the assay
medium by the vendors. The epidermal equivalents were then trans-
ferred under sterile conditions to a petri dish containing phosphate-
bu¡ered saline (PBS) for subsequent treatments.
2.2. Expression of ICAM-1
The HaCaT cells or HEK were washed in Dulbecco’s PBS, pH 7.4
(D-PBS) and incubated with £uorescein isothiocyanate (FITC)
coupled to ICAM-1 monoclonal antibody (Immunotech, Marseille,
France) for 30 min at 4‡C and washed once in D-PBS and ¢nally
resuspended in fresh D-PBS. Expression of ICAM-1 was immediately
assayed with a £ow cytometer. Appropriate isotypic controls were
used for background £uorescence in ICAM-1 assay. Flow cytometric
analyses were performed using the £uorescence and light scattering
properties (forward scatter, FS; side scatter, SS) as described before
[21].
2.3. Cell adhesion assay
Cell^cell adhesion was performed as previously described [21,22].
Brie£y, monolayers of HaCaT cells or HEK were seeded at a density
of 1U104 cells/well in 96-well tissue culture plates (Falcon 3072, Bec-
ton Dickinson, Franklin Lakes, NJ, USA). Calcein-AM (Molecular
Probes, Eugene, OR, USA)-labeled Jurkat T-cells (3U105 cells/well)
were co-cultured with HaCaT cells or HEK monolayers for 1 h in a
culture incubator with humidi¢ed air containing 5% CO2 at 37‡C. The
£uorescence intensity of each well was measured using a £uorescence
plate reader. The excitation and emission wavelengths for the calcein
molecule are 480 and 530 nm, respectively. The relative contributions
of ICAM-1 to the adherence of Jurkat T-cells to HaCaT cells or HEK
was evaluated by treating HaCaT cells or HEK with anti-human
ICAM-1 (10 Wg/ml) antibody (Beckman Coulter, Fullerton, CA,
USA) for 30 min prior to co-culture with Jurkat T-cells.
2.4. Real-time quantitative reverse transcription-polymerase chain
reaction (RT-PCR) analysis
Total RNA was extracted from HaCaT cells or HEK using guani-
dium isothiocyanate following the method of Chomczynski and
Sacchi [23]. Ampli¢cation reactions were performed with the Taq-
Man method (Perkin-Elmer Applied Biosystems, CA, USA). Primers
and the TaqMan probe for ICAM-1 were designed using the primer
design software Primer Express TM (Perkin-Elmer Applied Biosys-
tems). The sequences of the primers and TaqMan probes used in
this study are ICAM-1 forward primer; 5P-GCAATGTGCAAGAA-
GATAGCCA-3P, reverse primer; 5P-GTGAGGAAGGTTTTAGCT-
GTTGACTG-3P, probe; 5P-CCAATGTGCTATTCAAACTGCCCT-
GATGG-3P, GAPDH forward primer; 5P-GAAGGTGAAGGTCG-
GAGT-3P, reverse primer; 5P-GAAGATGGTGATGGGATTTC-3,
probe; 5P-CAAGCTTCCCGTTCTCAGCC-3P. Ampli¢cation of glyc-
eraldehyde-3-phosphate dehydrogenate (GAPDH) (TaqMan GAPDH
control reagent kit) was used as an endogenous control for quanti¢-
cation.
2.5. Electrophoretic mobility shift assay (EMSA)
The nuclear extracts were prepared and EMSAs were performed
essentially as described previously [21]. Binding reaction mixtures
(20 Wl) containing: 5 Wg protein of nuclear extract, 2 Wg poly(dI-dC)
(Pharmacia, Sweden), 32P-labeled STAT1 probe (Santa Cruz, CA,
USA), 50 mM NaCl, 2 mM MgCl2, 0.2 mM Na2EDTA, 1 mM di-
thiothreitol (DTT), 10% (v/v) glycerol and 4 mM Tris^HCl (pH 7.9)
were incubated for 30 min at room temperature. Proteins were sepa-
rated by electrophoresis in a native 6% polyacrylamide gel using a
Tris^borate^EDTA running bu¡er (12.5 mM Tris-borate containing
0.25 mM Na2EDTA, pH 8.0), followed by autoradiography.
2.6. Immunoprecipitation and immunoblot analysis
HaCaT cells were washed with ice-cold D-PBS containing 200 WM
sodium orthovanadate (Na3VO4), frozen immediately in liquid nitro-
gen, and then lysed in lysis bu¡er (25 mM Tris^HCl, pH 7.6, 200 mM
boric acid, 150 mM NaCl, 50 mM NaF, 5 mM Na2EDTA, 1% Triton
X-100, 10 mM sodium pyrophosphate, 2 mM EGTA, 20 mM p-nitro-
phenyl phosphate, 1% bovine serum albumin, 20 WM Na3VO4, 2 mM
DTT) containing protease inhibitors (2 Wg/ml each of aprotinin, leu-
peptin, pepstatin, antipain and 100 Wg/ml of phenylmethylsulfonyl
£uoride). Samples (20 Wg of protein each) were separated on 10%
sodium dodecyl sulfate (SDS)^polyacrylamide gel electrophoresis
(PAGE) and blotted onto Hybond-ECL nitrocellulose membranes
(Amersham Pharmacia Biotech, Piscataway, NJ, USA). The mem-
branes were blocked with 5% skim milk for 2 h at room temperature,
and then probed with a horseradish peroxidase (HRP)-conjugated
anti-phosphotyrosine antibody, PY20 (Santa Cruz, CA, USA) over-
night at 4‡C. Bound antibody was detected using the enhanced chem-
iluminescence Western blotting detection reagent (Amersham Pharma-
cia Biotech). Supernatants for immunoprecipitation were incubated at
4‡C with the anti-Janus kinase 1 (anti-JAK1) antibody (Santa Cruz,
CA, USA) bound to G-Sepharose beads (2 Wg of antibody per 20 Wl of
beads; Amersham Pharmacia Biotech) for 4 h, after which the beads
were washed twice with 1 ml of WG bu¡er (50 mM HEPES-NaOH,
pH 7.6, 150 mM NaCl, 0.1% Triton X-100) and resuspended in SDS
sample bu¡er.
2.7. Immunohistochemistry
Following topical application of taxifolin (20 WM) or DMSO, Epi-
Derm were activated with IFNQ 1000 U/ml for 12 h, and then the
tissues were immediately embedded in para⁄n. Slides were stained
with a streptavidin^biotin^peroxidase complex procedure using the
Dako CSA System, HRP (Dako, CA, USA) according to the manu-
facturer’s protocol. In brief, the sections were incubated at room
temperature for 30 min with an anti-human ICAM-1, CD54
(Dako). After three washes with PBS, the samples were incubated
with biotinylated anti-mouse IgG and the avidin^biotin complex at
room temperature for 15 min. Staining was completed by a 5-min
incubation with 3,3P-diaminobenzidine tetrahydrochloride.
2.8. Statistical analysis
Data are presented as meanSS.D. of at least three separate experi-
ments. Di¡erences between the means of groups were determined by
Student t-test and analysis of variance. The minimum level of signi¢-
cance was set at P6 0.05.
3. Results
3.1. IFNQ-induced expression of ICAM-1 in keratinocytes
Treatment of cells with IFNQ for 24 h resulted in increased
expression of ICAM-1 in HaCaT cells or primary HEK (Fig.
1). We have previously reported that IFNQ dose-dependently
(20^300 U/ml) induces ICAM-1 expression in HaCaT cells
[17]. Basal ICAM-1 expression levels were very low in unstim-
ulated cells. In subsequent experiments a 20 U/ml dose of
IFNQ was used. Treatment (24 or 48 h) of HaCaT cells or
HEK with tumor necrosis factor-K, which is a potent inducer
of ICAM-1 in endothelial cells, did not a¡ect the expression
of ICAM-1 (Fig. 1A). The e¡ect of various £avonoids on
IFNQ-induced ICAM-1 expression in HaCaT cells was inves-
tigated. Among all the £avonoids tested, taxifolin (100 WM,
12 h) was observed to be the most potent in inhibiting induc-
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ible ICAM-1 expression in HaCaT cells (Fig. 1B). To charac-
terize the kinetics of taxifolin-mediated inhibition of IFNQ-
induced expression of ICAM-1, HaCaT cells were pre-treated
with 100 WM taxifolin for di¡erent time periods followed by
activation with IFNQ for 24 h. Maximal inhibition (V60%
compared to non-treated activated cells) of inducible ICAM-
1 expression was observed in cells that were pre-treated with
taxifolin for 12 h (data not shown). Such down-regulation of
IFNQ-induced ICAM-1 expression by taxifolin was dose-de-
pendent in HaCaT cells (5^100 WM) as well as HEK (1^20
WM) (Fig. 2A). The e¡ect was already signi¢cant (P6 0.05) in
HaCaT cells or HEK with the 25 or 5 WM dose of taxifolin
pre-treatment, respectively. A lower concentration of taxifolin
was required in HEK cells to achieve a similar degree of in-
hibition as that achieved in HaCaT cells (Fig. 2A).
The non-permeant DNA intercalating dye propidium iodide
(Molecular Probes) was used to determine the viability of
HaCaT cells or HEK following treatment of the cells with
various doses of taxifolin [24]. The concentrations (up to
100 WM for HaCaT; 20 WM for HEK) of taxifolin were ob-
served to be not cytotoxic to the cells (data not shown).
3.2. Taxifolin inhibits IFNQ-induced adhesion of Jurkat cells to
keratinocytes
The co-culture assay was performed to verify whether the
inhibitory e¡ect of taxifolin on the expression of ICAM-1 was
also e¡ective in down-regulating actual cell to cell adhesion.
Pre-treatment of taxifolin (50 or 100 WM) for 12 h signi¢-
cantly inhibited the IFNQ-induced adherence of Jurkat T-cells
to HaCaT cells (Fig. 2B). Compared to the non-treated acti-
vated group, a 60% inhibition in cell adhesion was observed in
cells that were pre-treated with taxifolin (100 WM). Consistent
with the inhibitory e¡ect of taxifolin on inducible ICAM-1
expression in HEK, taxifolin pre-treatment dose-dependently
(1^20 WM) inhibited IFNQ-induced adherence of Jurkat cells
to HEK (Fig. 2B). Treatment of the cells prior to the adhesion
assay with ICAM-1 antibody inhibited 60^70% of the adher-
ence of Jurkat T-cells to HaCaT cells or HEK suggesting a
Fig. 1. Flavonoids down-regulate IFNQ-induced ICAM-1 expression in HaCaT. A: Flow cytometric analysis of the HaCaT cells and HEK acti-
vated with IFNQ (20 U/ml, 24 h) or TNF-K (20 ng/ml, 48 h). Broken and solid lines represent median value of log ICAM-1 FITC signal of
control (no treatment) cells and IFNQ-treated cells, respectively. Data are presented as histograms of cell number versus log ICAM-1 FITC
£uorescence intensity. Histograms are representative of three identical experiments. B: HaCaT cells were pre-treated with equal concentrations
(100 WM) of Api (apigenin, anthocyanidins), Qrct (quercetin, £avonol), Cat (catechin, £avanol), Fer A (ferulic acid, phenyl propanoids), Epi-
cat (epicatechin, £avanol), or Tax (taxifolin, £avanone) for 12 h, followed by activation with IFNQ (20 U/ml) for 24 h. ICAM-1 expression was
measured using a £ow cytometer. Data are presented as percent compared to the IFNQ-activated cells. Data are meanSS.D. of at least three
experiments.
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major role of ICAM-1 in IFNQ-induced adhesion of Jurkat
cells to keratinocytes (Fig. 2B).
3.3. Transcriptional regulation of IFNQ-induced ICAM-1
expression
ICAM-1 mRNA was markedly increased in HaCaT cells or
HEK treated with IFNQ (20 U/ml) for 4 h. Taxifolin pre-treat-
ment inhibited such an increase in ICAM-1 mRNA (Fig. 3A).
To investigate whether the inhibitory e¡ects of taxifolin on
inducible ICAM-1 mRNA expression is due to faster degra-
dation of the mRNA by taxifolin, the stability of ICAM-1
mRNA was studied. The cells were stimulated with IFNQ
alone for 4 h, and then actinomycin D (5Wg/ml) was added
to prevent further mRNA synthesis in the absence or presence
of taxifolin (100 WM). No signi¢cant di¡erence in the rates of
degradation of ICAM-1 mRNA in the presence or absence of
taxifolin was observed, indicating that the inhibitory e¡ect of
taxifolin on inducible ICAM-1 mRNA expression is not due
to the faster degradation of ICAM-1 mRNA by taxifolin (Fig.
3B).
The binding motif of the Q-activated sequence has been
identi¢ed in ICAM-1 promoter. Following activation, trans-
location of the STAT1 protein to nucleus and binding to the
Q-activated sequence motif plays a major role in the transcrip-
tional activation of IFNQ-induced ICAM-1 gene expression
[25]. The e¡ect of taxifolin on activation and nuclear trans-
location of STAT1 was investigated by EMSA. IFNQ treat-
ment to HaCaT cells resulted in activation and nuclear trans-
location of STAT1. A maximal increase in the nuclear
translocation of STAT1 was observed following 30 min of
IFNQ (20 U/ml) treatment [17]. Taxifolin pre-treatment for
12 h dose-dependently (10^100 WM) decreased IFNQ-mediated
activation of STAT1 in HaCaT cells (Fig. 4A). In HEK, the
dose (20 WM, 12 h) of taxifolin that is required to inhibit
inducible ICAM-1 protein and mRNA expression also e¡ec-
tively inhibited the IFNQ-mediated activation of STAT1 (Fig.
4A).
3.4. Tyrosine phosphorylation regulates IFNQ-induced ICAM-1
expression
Activation of IFNQ-responsive genes requires tyrosine phos-
phorylation of the transcriptional factor STAT1. Tyrosine ki-
nase inhibitor, herbimycin A was used to investigate the role
of tyrosine phosphorylation in the regulation of IFNQ-induced
ICAM-1 expression in HaCaT cells and HEK. Herbimycin A
(1 WM) pre-treatment for 15 min to HaCaT cells or HEK
markedly inhibited IFNQ-induced ICAM-1 expression as
well as the inducible adherence of Jurkat cells to keratinocytes
(Fig. 2). Herbimycin A pre-treatment also potently inhibited
the IFNQ-induced ICAM-1 mRNA expression (Fig. 3A) and
STAT1 activation (data not shown). The role of reactive oxy-
gen species in the pathway was also explored using potent
anti-oxidants such as K-lipoate or N-acetylcysteine, however,
the suppressive e¡ect achieved by these anti-oxidants on the
Fig. 2. E¡ect of taxifolin pre-treatment on IFNQ-induced ICAM-1 expression and cell adhesion. A: HaCaT cells or HEK were pre-treated with
taxifolin for 12 h or herbimycin A (1 WM) for 15 min followed by activation with IFNQ (20 U/ml) for 24 h. Data are meanSS.D. of at least
three experiments. B: HaCaT cells or HEK were pre-treated with taxifolin for 12 h or herbimycin A (1 WM) for 15 min, and then activated
with 20 U/ml IFNQ for 24 h. The cells were washed three times with D-PBS and then co-cultured with calcein-AM-labeled Jurkat T-cells for
1 h. The relative contribution of ICAM-1 in inducible cell^cell adhesion was determined by incubating cells with ICAM-1 blocking antibody
(10 Wg/ml) for 30 min prior to the assay. Data are meanSS.D. of at least three experiments. *P6 0.01 or **P6 0.05 when compared with taxi-
folin non-treated IFNQ-activated group.
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IFNQ-induced ICAM-1 expression was much smaller com-
pared to that by herbimycin A or taxifolin (not shown). Her-
bimycin A data suggested that protein tyrosine phosphoryla-
tion was involved in the transcriptional regulation of IFNQ-
induced ICAM-1 expression in HaCaT cells and HEK. Thus,
to con¢rm whether the mode of action of taxifolin in inhibit-
ing inducible ICAM-1 is via a¡ecting the inducible tyrosine
phosphorylation, the cells were pre-treated with taxifolin and
then activated with IFNQ. Overall protein tyrosine phosphor-
ylation was investigated by Western blot using phosphotyro-
sine speci¢c antibody. IFNQ (20 U/ml) activation induced pro-
tein tyrosine phosphorylation in HaCaT cells. Speci¢cally, one
major band around 130 kDa was heavily phosphorylated fol-
lowing IFNQ treatment. Maximal activation in this band was
observed following 15 min exposure to IFNQ. Taxifolin (100
WM) treatment of the cells for 12 h resulted in a marked in-
hibition of IFNQ-induced phosphorylation of the 130 kDa
band (data not shown). Since the molecular weight of
JAK1, JAK2 or Tyk2, which mediates IFNQ signaling, is
around 130 kDa, phosphorylation of the tyrosine residue of
these kinases was analyzed by immunoprecipitation. Immuno-
precipitation with anti-JAK1, anti-JAK2 or anti-Tyk2 anti-
body and blotting with anti-phosphotyrosine antibody
(PY20) con¢rmed that the 130 kDa band is JAK1 protein
(Fig. 4B), because we could not detect the phosphorylation
of JAK2 or Tyk2 by IFNQ in HaCaT cells. Thus, JAK1 ap-
peared to be a potential candidate for taxifolin-mediated
down-regulation of IFNQ-induced phosphorylation.
3.5. Taxifolin suppressed IFNQ-induced ICAM-1 expression in
a reconstructed human skin model
To verify physiological relevance of taxifolin treatment in
in£ammatory skin disorders, the e¡ect of taxifolin on IFNQ-
induced ICAM-1 expression was evaluated in a reconstructed
human skin model (EpiDerm). Because of a plastic cup that
surrounds the 3D human skin model it is possible to regulate
the actual volume of the medium as well as the exact concen-
tration of reagents applied to the model. To obtain su⁄cient
ICAM-1 expression levels in EpiDerm that are detectable by
immunohistochemical analysis, a relatively high dose (1000 U/
ml) of IFNQ was used. Regardless of the high dose of IFNQ
used for ICAM-1 expression, topical application of taxifolin
as low as 20 WM for 12 h markedly suppressed IFNQ-induced
ICAM-1 expression in EpiDerm (Fig. 5).
4. Discussion
Adhesion of T-cells to keratinocytes is a key feature in skin
in£ammation processes [26,27]. The present study provides the
¢rst evidence that among various £avonoids tested, taxifolin
is a potent inhibitor of IFNQ-induced adherence of Jurkat
T-cells to keratinocytes. Such e¡ect of taxifolin on inducible
cell^cell adhesion was mediated via its inhibitory e¡ect on
ICAM-1 expression. The maximum e¡ect of taxifolin on in-
ducible ICAM-1 was observed following 12 h of pre-treatment
suggesting that native taxifolin is not active in inhibiting in-
ducible ICAM-1 expression. A 12 h period required to achieve
Fig. 3. E¡ect of taxifolin on IFNQ-activated ICAM-1 mRNA. A: Cells were pre-treated with taxifolin for 12 h and then activated with IFNQ
(20 U/ml) for 4 h. HaCaT cells were also pre-treated with herbimycin A (1 WM) for 15 min and then activated with IFNQ. B: HaCaT cells
were treated with IFNQ (20 U/ml) for 4 h, and then treated further with actinomycin D (Act D; 5 Wg/ml), either alone (F) or with taxifolin (b,
100 WM) for time period indicated (hour). Relative mRNA levels of ICAM-1 were determined by quantitative RT-PCR of HaCaT cells or
HEK with or without activation of IFNQ. Expression of ICAM-1 mRNA is in arbitrary units, and data are normalized to non-activated cells.
GAPDH was selected as an endogenous RNA control to normalize for di¡erences in the amount of total RNA. Data are representative of
three independent experiments.
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Fig. 4. E¡ect of taxifolin pre-treatment on IFNQ-mediated activation of STAT1 and JAK1. A: HaCaT cells were pre-treated with taxifolin (10^
100 WM) for 12 h and then activated with IFNQ (20 U/ml) for 0.5 h; and HEK was also pre-treated with taxifolin (20 WM) and then activated
with IFNQ (20 U/ml) for 0.5 h. Nuclear translocation of STAT1 was determined by EMSA. The speci¢city of the DNA binding complex was
evaluated by competition with excess unlabeled (cold) STAT1 oligonucleotide. B: HaCaT cells were pre-treated with taxifolin (100 WM) for 12 h
and then activated with 20 U/ml IFNQ for 15 min. Cell lysates were then extracted from IFNQ-stimulated and unstimulated HaCaT cells and
subjected to immunoprecipitation (IP) with the anti-JAK1 antibody. The immunoprecipitates were run on a SDS^PAGE and subjected to im-
munoblot analysis with PY20. The same membrane was then reprobed with the anti-JAK1 antibody. Data are representative of three indepen-
dent experiments.
Fig. 5. Topical application of taxifolin on IFNQ-induced ICAM-1 expression in a 3D model of human skin epidermis. EpiDerm were treated
with DMSO (0.5% v/v) or taxifolin (20 WM) for 12 h, and then incubated with 1000 U/ml IFNQ for 12 h. ICAM-1 expression is seen in the cy-
toplasm of most keratinocytes of IFNQ treated EpiDerm (middle panel), whereas little ICAM-1 expression is seen in non-treated EpiDerm (left
panel). Topical application of taxifolin suppressed IFNQ-induced ICAM-1 expression (right panel). Left panel: DMSO only; middle panel:
DMSO+IFNQ ; right panel: taxifolin+IFNQ. Data are representative of two independent experiments.
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the maximal inhibitory e¡ect on ICAM-1 may be due to the
rate of uptake of taxifolin in cells or cellular activation/trans-
formation of taxifolin being required to achieve the observed
e¡ect. The study also provides the ¢rst evidence that topical
application of a low concentration (20 WM) of a naturally
occurring £avonoid taxifolin markedly inhibits IFNQ-induced
ICAM-1 expression in a reconstructed human skin model.
The observation that much lower dosages of taxifolin are
required in HEK (primary cells) to achieve the comparable
e¡ects on inducible ICAM-1 expression observed in HaCaT
suggests that data obtained using immortalized cells should be
interpreted with caution in terms of the e¡ective concentra-
tion.
IFNQ-dependent induction of ICAM-1 expression is regu-
lated at the transcriptional level [28]. Marked suppression of
the IFNQ-mediated increase in ICAM-1 mRNA by taxifolin
without a¡ecting the stability of ICAM-1 mRNA level sug-
gests that regulation of inducible ICAM-1 expression in ker-
atinocytes is at a transcriptional level. The 5P-prime £anking
region of ICAM-1 gene contains an 11-basepair element,
which is referred to as the palindromic IFNQ response element
(RE), or pIQRE, located upstream of the ICAM-1 transcrip-
tion initiation site between nucleotides 376 and 66. The
pIQRE is composed of the sequence 5P-TTTCCGGGAAA-3P
[29]. It has been demonstrated that pIQRE is both necessary
and su⁄cient for IFNQ-dependent gene transcription [29].
pIQRE is homologous to IFNQ-activated sequences, which
bind to tyrosine phosphorylated members of the transcription
factor family known as STAT [30]. pIQRE consists of a DNA
element common to all IFN-responsive genes (GAAA) with a
distinct £anking sequence (the inverted repeat GAAA) in or-
der to ¢ne-tune IFN responses and activate a subset of im-
mune response genes such as ICAM-1 or IRF-1 [30^32]. The
¢rst member of the STAT family (designated as STAT1) is
critical for IFNQ-dependent gene activation [29]. Taxifolin
dose-dependently inhibited nuclear translocation of STAT1
in HaCaT cells as well as HEK.
IFNQ, a homodimeric molecule, bivalently binds to its re-
ceptor and activates the JAK/STAT pathway by clustering its
receptor. The Janus family of tyrosine kinases is an integral
component of IFNQ-activated signaling cascades, which regu-
late tyrosine phosphorylation of the STAT proteins such that
they can translocate to the nucleus and bind DNA [33]. IFNQ
stimulates tyrosine phosphorylation within the cytoplasmic
domain of its receptor this event occurs concomitantly with
tyrosine phosphorylation of both JAK1 and JAK2 [25]. A
distinct band of 130 kDa was heavily phosphorylated follow-
ing IFNQ activation. Probing the membrane with anti-JAK1
antibody demonstrated that the 130 kDa band is JAK1 pro-
tein. Taxifolin signi¢cantly inhibited tyrosine phosphorylation
of this 130 kDa band suggesting that one of the potential sites
of action of taxifolin in inhibiting inducible ICAM-1 is by
down-regulating phosphorylation of JAK1. As the similar ef-
fects were observed by herbimycin A treatment, further mech-
anism of action of taxifolin which is distinguishable from that
of herbimycin A will be of interest for future study.
Regulation of ICAM-1 gene expression has been related to
oxidative stress through speci¢c reduction^oxidation (redox)
sensitive transcriptional regulation [34]. The inhibitory e¡ect
of taxifolin on inducible ICAM-1 expression may be due to its
anti-oxidant activity. The analysis of structure^anti-oxidant
activity relationships using Trolox equivalent anti-oxidant ca-
pacity has demonstrated that taxifolin has less anti-oxidant
potential than that of the other £avonoids such as quercetin
[35] that did not signi¢cantly change inducible ICAM-1 ex-
pression in keratinocytes. These data suggest that it is less
likely that the anti-oxidant activity of taxifolin is mainly re-
sponsible for its inhibitory e¡ect on the inducible ICAM-1
expression though the contribution of redox state may not
be ruled out completely.
De novo expression of ICAM-1 in keratinocytes is an im-
portant initiator of T-cell/keratinocyte interactions in many
in£ammatory skin diseases [26,27]. The marked inhibition of
IFNQ-induced ICAM-1 expression by taxifolin was observed
in a 3D human skin model. In conclusion this study provides
therapeutic potential of this £avonoid in skin pathological
conditions related to increased cell adhesion and in£amma-
tion.
Acknowledgements: We are grateful to Nguyen Hao for technical as-
sistance.
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